## Masayuki Mizui

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8399024/publications.pdf

Version: 2024-02-01

159585 3,038 64 30 citations h-index papers

g-index 66 66 66 4258 docs citations times ranked citing authors all docs

161849

54

#	Article	IF	CITATIONS
1	Reduction of Cell Surface T-Cell Receptor by Non-Mitogenic CD3 Antibody to Mitigate Murine Lupus. Frontiers in Immunology, 2022, 13, 855812.	4.8	1
2	Single cell RNA sequencing uncovers cellular developmental sequences and novel potential intercellular communications in embryonic kidney. Scientific Reports, 2021, 11, 73.	3.3	8
3	Genetic Background and Clinicopathologic Features of Adult-onset Nephronophthisis. Kidney International Reports, 2021, 6, 1346-1354.	0.8	14
4	Editorial: Focusing on T-Cells for Novel Treatments of Systemic Lupus Erythematosus. Frontiers in Immunology, 2021, 12, 744866.	4.8	2
5	The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8ÂT Cell Function and Identifies Patients with SLE Prone to Infections. Cell Reports, 2020, 30, 112-123.e4.	6.4	102
6	Animal Models: Systemic Autoimmune Diseases. , 2020, , 533-551.		1
7	P1276EXPLORING POSSIBLE PREDICTORS OF STRUCTURAL DETERIORATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION IN HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
8	THU0236â€EFFICACY AND SAFETY OF NON-MITOGENIC ANTICD3 ANTIBODY ADMINISTRATION IN THE TREATM OF LUPUS-PRONE MICE. Annals of the Rheumatic Diseases, 2020, 79, 345.1-345.	ENT,	0
9	Dynamics of d-serine reflected the recovery course of a patient with rapidly progressive glomerulonephritis. CEN Case Reports, 2019, 8, 297-300.	0.9	12
10	VEGF-A Links Angiolymphoid Hyperplasia With Eosinophilia (ALHE) to THSD7A Membranous Nephropathy: A Report of 2 Cases. American Journal of Kidney Diseases, 2019, 73, 880-885.	1.9	20
11	Natural and modified IL-2 for the treatment of cancer and autoimmune diseases. Clinical Immunology, 2019, 206, 63-70.	3.2	53
12	Semaphorin4D-PlexinB1 Signaling Attenuates Photoreceptor Outer Segment Phagocytosis by Reducing Rac1 Activity of RPE Cells. Molecular Neurobiology, 2018, 55, 4320-4332.	4.0	14
13	Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study. Clinical and Experimental Nephrology, 2018, 22, 550-561.	1.6	9
14	Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 786.	4.8	56
15	Severe Osteomalacia with Dent Disease Caused by a Novel Intronic Mutation of the <i>CLCN5</i> gene. Internal Medicine, 2018, 57, 3603-3610.	0.7	5
16	Monoclonal immunoglobulin-associated proliferative glomerulonephritis characterized by organized deposits of striated ultra-substructures: A case report. Ultrastructural Pathology, 2017, 41, 301-307.	0.9	4
17	Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective. Trends in Molecular Medicine, 2017, 23, 615-635.	6.7	328
18	The Authors Reply. Kidney International, 2017, 91, 989-990.	<b>5.</b> 2	0

#	Article	IF	Citations
19	MP057VASCULAR ENDOTHELIAL GROWTH FACTOR A LINKS ANGIOLYMPHOID HYPERPLASIA WITH EOSINOPHILIA TO MEMBRANOUS NEPHROPATHY. Nephrology Dialysis Transplantation, 2017, 32, iii446-iii446.	0.7	0
20	Critical renal adverse event induced by nivolumab therapy in a stage IV melanoma patient. Journal of Dermatology, 2017, 44, 727-728.	1.2	10
21	Calcium/Calmodulinâ€Dependent Kinase IV Facilitates the Recruitment of Interleukinâ€17–Producing Cells to Target Organs Through the CCR6/CCL20 Axis in Th17 Cell–Driven Inflammatory Diseases. Arthritis and Rheumatology, 2016, 68, 1981-1988.	5.6	41
22	N-WASP is required for B-cell–mediated autoimmunity in Wiskott-Aldrich syndrome. Blood, 2016, 127, 216-220.	1.4	24
23	Low-Dose IL-2 in the Treatment of Lupus. Current Rheumatology Reports, 2016, 18, 68.	4.7	37
24	Engagement of SLAMF3 enhances CD4 <sup>+</sup> T-cell sensitivity to IL-2 and favors regulatory T-cell polarization in systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9321-9326.	7.1	30
25	An unusual case of acute kidney injury afterÂcolonoscopy. Kidney International, 2016, 90, 711.	5.2	2
26	ICER is requisite for Th17 differentiation. Nature Communications, 2016, 7, 12993.	12.8	64
27	Deficiency of base excision repair enzyme NEIL3 drives increased predisposition to autoimmunity. Journal of Clinical Investigation, 2016, 126, 4219-4236.	8.2	56
28	Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. Journal of Clinical Investigation, 2016, 126, 2077-2092.	8.2	56
29	FRI0018â€CAMK4 Inhibition Prevents Recruitment of IL-17 Producing Cells to Target Organs Through CCR6/CCL20 Axis in TH17 Driven Inflammatory Diseases. Annals of the Rheumatic Diseases, 2015, 74, 425.1-425.	0.9	0
30	Complement receptor of the immunoglobulin superfamily reduces murine lupus nephritis and cutaneous disease. Clinical Immunology, 2015, 160, 286-291.	3.2	25
31	Cutting Edge: Nanogel-Based Delivery of an Inhibitor of CaMK4 to CD4+ T Cells Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-like Disease in Mice. Journal of Immunology, 2015, 195, 5533-5537.	0.8	53
32	Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL/lpr mice. Clinical Immunology, 2015, 158, 221-230.	3.2	59
33	CD16+CD56+ cells are a potential culprit for hematuria in IgA nephropathy. Clinical and Experimental Nephrology, 2015, 19, 216-224.	1.6	13
34	IL-2 Protects Lupus-Prone Mice from Multiple End-Organ Damage by Limiting CD4â^'CD8â^' IL-17–Producing T Cells. Journal of Immunology, 2014, 193, 2168-2177.	0.8	105
35	KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3 <sup>+</sup> regulatory T cells in MRL/ <i>lpr</i> https://www.autoimmunity.com/sup/sup/sup/sup/sup/sup/sup/sup/sup/sup	2.6	60
36	Systemic Lupus Erythematosus, Animal Models. , 2014, , 1134-1141.		0

#	Article	IF	Citations
37	THU0057â€Kn-93, an Inhibitor of Calcium/Calmodulin-Dependent Protein Kinase Iv, Promotes Generation and Function of Foxp3+ Regulatory T Cells in Mrl/Lpr Mice. Annals of the Rheumatic Diseases, 2014, 73, 195.3-196.	0.9	0
38	CaMK4-dependent activation of AKT/mTOR and CREM- $\hat{l}\pm$ underlies autoimmunity-associated Th17 imbalance. Journal of Clinical Investigation, 2014, 124, 2234-2245.	8.2	185
39	An Inhibitory Role for Sema4A in Antigen-Specific Allergic Asthma. Journal of Clinical Immunology, 2013, 33, 200-209.	3.8	27
40	The Catalytic Subunit of Protein Phosphatase 2A (PP2Ac) Promotes DNA Hypomethylation by Suppressing the Phosphorylated Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (ERK) Kinase (MEK)/Phosphorylated ERK/DNMT1 Protein Pathway in T-cells from Controls and Systemic Lupus Erythematosus Patients. Journal of Biological Chemistry, 2013, 288, 21936-21944.	3.4	91
41	B cell–intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in mice. Blood, 2012, 119, 2819-2828.	1.4	99
42	Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses IL-2 Production and Regulatory T Cell Activity in Lupus. Journal of Immunology, 2012, 189, 3490-3496.	0.8	91
43	A Superagonistic Monoclonal Antibody for CD28 Ameliorates Crescentic Glomerulonephritis in Wistar-Kyoto Rats. Molecular Medicine, 2011, 17, 686-696.	4.4	8
44	Cutting Edge: Calcium/Calmodulin-Dependent Protein Kinase Type IV Is Essential for Mesangial Cell Proliferation and Lupus Nephritis. Journal of Immunology, 2011, 187, 5500-5504.	0.8	66
45	Semaphorins guide the entry of dendritic cells into the lymphatics by activating myosin II. Nature Immunology, 2010, 11, 594-600.	14.5	188
46	Immune Semaphorins: Novel Features of Neural Guidance Molecules. Journal of Clinical Immunology, 2009, 29, 1-11.	3.8	53
47	Superagonistic CD28 Antibody Induces Donor-Specific Tolerance in Rat Renal Allografts. American Journal of Transplantation, 2008, 8, 2004-2014.	4.7	26
48	Neuropilin-1: The Glue between Regulatory T Cells and Dendritic Cells?. Immunity, 2008, 28, 302-303.	14.3	24
49	Plexin-A4 negatively regulates T lymphocyte responses. International Immunology, 2008, 20, 413-420.	4.0	74
50	Bimodal regulation of T cell-mediated immune responses by TIM-4. International Immunology, 2008, 20, 695-708.	4.0	64
51	Chemically modified siRNA prolonged RNA interference in renal disease. Biochemical and Biophysical Research Communications, 2007, 363, 432-437.	2.1	40
52	Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. Nature Cell Biology, 2006, 8, 615-622.	10.3	229
53	Transcription factor Ets-1 is essential for mesangial matrix remodeling. Kidney International, 2006, 70, 298-305.	5.2	23
54	Targeting of interstitial cells using a simple gene-transfer strategy. Nephrology Dialysis Transplantation, 2006, 21, 2745-2753.	0.7	11

#	Article	IF	CITATIONS
55	Exploring RNA interference as a therapeutic strategy for renal disease. Gene Therapy, 2005, 12, 965-973.	4.5	88
56	Electroporation-mediated HGF gene transfection protected the kidney against graft injury. Gene Therapy, 2005, 12, 815-820.	4.5	30
57	Requirement for CD100–CD72 interactions in fine-tuning of B-cell antigen receptor signaling and homeostatic maintenance of the B-cell compartment. International Immunology, 2005, 17, 1277-1282.	4.0	57
58	Nonredundant Roles of Sema4A in the Immune System: Defective T Cell Priming and Th1/Th2 Regulation in Sema4A-Deficient Mice. Immunity, 2005, 22, 305-316.	14.3	147
59	Electroporation-mediated HGF gene transfer ameliorated cyclosporine nephrotoxicity. Kidney International, 2004, 65, 2041-2053.	5.2	36
60	DNAzyme for TGF- $\hat{l}^2$ suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney International, 2004, 66, 586-590.	5.2	28
61	Gene therapy in renal diseases. Kidney International, 2004, 65, 1551-1555.	5.2	22
62	Antisense Oligonucleotides Against Thrombospondin-1 Inhibit Activation of TGF-β in Fibrotic Renal Disease in the Rat in Vivo. American Journal of Pathology, 2003, 163, 1185-1192.	3.8	67
63	Low-dose interleukin-2 as a regulatory immunotherapy for systemic lupus erythematosus. Journal of Xiangya Medicine, $0, 1, 15-15$ .	0.2	0
64	Low-dose interleukin-2 as a regulatoy immunetherapy for systemic lupus erythematosus. Xiangya Medicine, 0, 1, 42-42.	0.0	0